Evaluating patient reported outcomes in the treatment practice of patients with rheumatoid arthritis
Recruiting
- Conditions
- Patient Reported Outcomes, PROsRheumatoid Arthritis, RA Intensive outpatient management Tight Control Treat to target (T2T)
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
Adults with reumatoïde artritis treated with biologicals, such as TNFα-blockers (etanercept, adalimumab, infliximab etc.), interleukine-I-blockers, the B-celblocker rituximab, and the T-celactivationblocker and anti CTLA4 (abatacept).
Exclusion Criteria
non RA patients, no biological treatment, non adult,
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patient reported outcomes (RAPID-3) and DAS28
- Secondary Outcome Measures
Name Time Method Side effects
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie patient-reported outcomes in rheumatoid arthritis treatment practices?
How does intensive outpatient management compare to standard care in rheumatoid arthritis patient-reported outcomes?
What biomarkers are associated with response prediction in tight control treat-to-target rheumatoid arthritis strategies?
What adverse events are commonly reported in rheumatoid arthritis trials using patient-reported outcome measures?
How do combination therapies for rheumatoid arthritis impact patient-reported outcomes compared to monotherapies?